Glaukos Corporation stocks have been trading up by 7.84 percent following strong glaucoma treatment data fueling investor optimism.
What Traders Need To Know
- Citi lifted its Glaukos price target to $162 and kept a Buy rating, flagging Epioxa as a major, underappreciated growth engine.
- Needham raised its target to $150 with a Buy rating, seeing Epioxa offset possible iDose reimbursement pressure by 2027.
- Street consensus on Glaukos sits at an average Buy rating with a mean target of $157.50, above recent trading levels.
- Phase 2 enrollment for GLK-321 in Demodex blepharitis is complete at 275 US patients, with a six-week collarette-elimination endpoint.
- Recent amended Form 4/A filings reflect updated insider ownership records, with no new large buying or selling disclosed.
Weekly Update Jun 29 – Jul 03, 2026: On Saturday, July 04, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 7.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Glaukos holds a leading position in MIGS and emerging corneal/ocular surface therapeutics, with revenue growing 24% three-year CAGR to ~$508M but still materially loss-making. Gross margin is robust at 57.6%, yet EBIT margin is -34.5% and ROE about -26%, reflecting heavy R&D and SG&A to build the platform. Balance sheet quality is strong: debt-to-equity 0.15, current ratio 5.4, and ~$277M in cash/short-term investments, giving ample runway despite negative free cash flow.
Technically, GKOS remains in a strong intermediate uptrend, with weekly prices rebounding from ~$138 to ~$148–142 and tight ranges indicating consolidation after a sharp prior advance. Recent 5-minute action has shown buyers repeatedly defending the mid-$130s with increasing volume on up-swings and lighter volume on pullbacks, consistent with institutional accumulation. A clear actionable level is $137–138: above it, risk-on long bias; a decisive break below would signal a deeper correction toward low-$130s.
More Breaking News
- AAL Stock Slides As Fuel Shock Slams 2026 Outlook
- BMNR Stock Pulls Back As Traders Gauge Risk
- Global Payments Stock Climbs As Analysts Hike Price Targets
- AVGO Stock Firms Up As Broadcom Shows Strong Profits And Cash
Fundamentally and sentiment-wise, the setup is favorable versus broader Healthcare and MedTech, which grow mid-single digits with mixed margin trends. Street upgrades (Citi $162, Needham $150, average target ~$157.50) reflect rising confidence in Epioxa as the next major growth driver and in the expanding iLution/ocular surface pipeline, including GLK-321 phase 2 enrollment completion. I see upside to $155–165 over 12–18 months, with strong support in the $130–135 zone and resistance near $150–155.
Quick Financial Overview
Glaukos Corporation (GKOS) is trading in a strong uptrend, with weekly data showing a rebound from $137.57 to $148.35 in a matter of days. The intraday 5-minute bar captures a wide range from $136.18 to $148.62, closing near the high at $148.34. That type of close shows aggressive dip buying and suggests traders are willing to pay up into strength when positive catalysts hit.
On the fundamentals, Glaukos posted quarterly revenue of about $150.6M, backed by a robust gross margin of 57.6%. Full-year revenue of roughly $507.4M is growing fast, with 3-year and 5-year growth rates around 24% and 18%. The flip side is profitability: EBIT margin near -34.5% and a recent quarterly net loss of about $19.8M point to a company still investing heavily in growth rather than generating earnings.
Liquidity and balance sheet strength are key for a name like GKOS. Current and quick ratios of 5.4 and 4.4 indicate ample near-term funding capacity, while total debt-to-equity of 0.15 is modest for a growth medtech. Cash and equivalents above $100M, plus operating cash burn of about $12.5M last quarter and negative free cash flow of roughly $16.5M, tell traders that Glaukos can likely fund its pipeline, but ongoing losses keep it a higher-beta, news-driven trade.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.